Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + lenvatinib + irinotecan liposomes
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of the PD-1 inhibitor tislelizumab, the multi-kinase inhibitor lenvatinib, and a liposomal formulation of the cytotoxic agent irinotecan. It is being investigated by the Anhui Provincial Cancer Hospital for the treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC). Tislelizumab is a humanized IgG4 monoclonal antibody that enhances the anti-tumor immune response by blocking the PD-1/PD-L1 pathway. Lenvatinib targets multiple receptor tyrosine kinases, including VEGFR and FGFR, to inhibit angiogenesis and tumor cell proliferation, while also potentially modulating the tumor microenvironment to enhance immunotherapy. Irinotecan liposomes provide a sustained-release formulation of the topoisomerase I inhibitor, leading to DNA damage and apoptosis in rapidly dividing cancer cells. The regimen aims to provide synergistic anti-tumor activity through immune activation, anti-angiogenesis, and direct cytotoxicity.
- Other names
- tislelizumab + renvastinib + irinotecan liposomes
02
Targets
TOP1 (DNA Topoisomerase I)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on tislelizumab + lenvatinib + irinotecan liposomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + lenvatinib + irinotecan liposomes.